Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares, a company specializing in automated manufacturing platforms for cell therapies. This marks the second collaboration between the two entities, focusing on the production of an unnamed CAR-T cell therapy. The agreement highlights BMS’s commitment to leveraging advanced manufacturing technologies to enhance the efficiency and scalability of CAR-T cell production.
Advantages of Automated Manufacturing
Cellares’s contract manufacturing organization (CMO) services are positioned as a cost-efficient and scalable solution for both autologous and allogeneic cell therapies across various modalities. The company’s platform can be integrated within a short timeframe of six months, which is crucial for accelerating the development and manufacturing of life-saving therapies.
Significance of the Agreement
This technology transfer agreement with Cellares underscores BMS’s strategic approach to adopting innovative manufacturing processes. By leveraging Cellares’s automated platform, BMS aims to improve the production capabilities for their CAR-T cell therapies, potentially reducing costs and increasing accessibility for patients in need of these advanced treatments.
Conclusion
The partnership between Bristol-Myers Squibb and Cellares represents a significant step forward in the field of CAR-T cell therapy manufacturing. With the aim to enhance both the efficiency and scalability of production, this agreement is set to contribute to the advancement of personalized medicine and improve patient outcomes.-Fineline Info & Tech
